Most Read Articles
29 Nov 2019
Metformin Extended Release 500 mg,750 mg, and 1000 mg
Pearl Toh, Yesterday
Getting just under one extra hour of sleep per night can go a long way for the health of college students, who are often sleep-deprived, a study suggests.
29 Nov 2019
Saxagliptin 5 mg, dapagliflozin 10 mg FC tab
Roshini Claire Anthony, 5 days ago

The CA125* test could be useful at detecting ovarian cancer and various other cancers in the primary care setting, particularly for women aged >50 years, according to a study presented at the recent NCRI** Cancer Conference held in Glasgow, Scotland, UK.

Product Highlight - QTERN

29 Nov 2019
• Superior HbA1c reduction vs DPP4i +Met or SGLT2i +Met1

• Nearly 2x patients achieved HbA1c <7%1

• Established safety profile of DPP4i with additional benefits of SGLT2i3,5-8

• Extends oral therapy with a once daily tablet4-7



References:
1. Rostenstock J, et al. Diabetes Care 2015; 38(3):376·383.
2. T. Vilsboll, et al. Dapagliflozin plus Saxagliptin shows noninferior HbA1c reductions vs insulin Glargine in patients with Type 2 Diabetes Inadequately.
3. Qtern Malaysia Prescribing Information, AstraZeneca, 2019.
4. Lokhandwala T, et al. J Med Econ. 2016: 19: 203-12.
5. Del Prato S, et al. Diabetes Obes Metab 2018; 20: 1542·1546.
6. Matthaei S, et al. Diabetes Care. 2015: 38: 2018-2024.
7. Bailey CJ, et aI. Lancet 2010; 37: 2233-33.
8. Del Prato S, et al. Diabetes Obes Metab 2015;17: 581-90.

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
29 Nov 2019
Metformin Extended Release 500 mg,750 mg, and 1000 mg
Pearl Toh, Yesterday
Getting just under one extra hour of sleep per night can go a long way for the health of college students, who are often sleep-deprived, a study suggests.
29 Nov 2019
Saxagliptin 5 mg, dapagliflozin 10 mg FC tab
Roshini Claire Anthony, 5 days ago

The CA125* test could be useful at detecting ovarian cancer and various other cancers in the primary care setting, particularly for women aged >50 years, according to a study presented at the recent NCRI** Cancer Conference held in Glasgow, Scotland, UK.